Inhibikase Therapeutics, Inc.
IKT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $261 | $123 | $3,101 |
| % Growth | -100% | 111% | -96% | – |
| Cost of Goods Sold | $26 | $13,618 | $7 | $11,359 |
| Gross Profit | -$26 | -$13,358 | $117 | -$8,258 |
| % Margin | – | -5,127.8% | 94.6% | -266.4% |
| R&D Expenses | $17,211 | $13,618 | $12,035 | $11,359 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $11,379 | $6,732 | $6,210 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$26 | -$13,618 | $0 | -$4,851 |
| Operating Expenses | $28,563 | $6,732 | $18,245 | $6,508 |
| Operating Income | -$28,589 | -$20,090 | -$18,129 | -$14,766 |
| % Margin | – | -7,712% | -14,686.2% | -476.2% |
| Other Income/Exp. Net | $1,069 | $1,061 | $74 | -$20 |
| Pre-Tax Income | -$27,520 | -$19,029 | -$18,054 | -$14,786 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$27,520 | -$19,029 | -$18,054 | -$14,786 |
| % Margin | – | -7,304.8% | -14,625.9% | -476.9% |
| EPS | -1.16 | -3.57 | -4.26 | -4.88 |
| % Growth | 67.5% | 16.2% | 12.7% | – |
| EPS Diluted | -1.16 | -3.57 | -4.26 | -4.88 |
| Weighted Avg Shares Out | 69,362 | 5,333 | 4,202 | 3,035 |
| Weighted Avg Shares Out Dil | 69,362 | 5,333 | 4,202 | 3,035 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,069 | $1,061 | $74 | $20 |
| Interest Expense | $0 | $0 | $74 | $20 |
| Depreciation & Amortization | $26 | $177 | $7 | $14,766 |
| EBITDA | -$27,494 | -$19,912 | -$18,047 | $0 |
| % Margin | – | -7,643.9% | -14,620.4% | 0% |